Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.
While cancer continues to be one of the leading causes of death and illness, new technology and increasing use of real-world data have the potential to revolutionise care.
